Email Facebook Twitter

Exclusive: Hardman & Co call the lithium market: is a change in trend happening?
Tower Resources identify 18 million barrels of contingent reserves worth $118M in Cameroon

Alliance News

Amryt Pharma Enrols First Patient In Epidermolysis Bullosa Trial

Mon, 24th Apr 2017 12:42

LONDON (Alliance News) - Amryt Pharma PLC on Monday said it has enrolled its first patient into its phase III clinical trial of AP101 as a potential treatment for epidermolysis bullosa.

Epidermolysis bullosa is a disease that causes the skin to tear and blister on being touched.

The phase III trial will study 164 patients across 30 sites in 15 countries, with the first site initiated in Sydney, Australia.

"We are delighted to enrol the first patient in EASE, our pivotal Phase 3 clinical trial. The trial will evaluate the efficacy and safety of our lead drug candidate, AP101, as a potential treatment for Epidermolysis Bullosa, a distressing and rare skin disorder. We look forward to further patients joining the study, which we expect to be one of the largest studies of its kind in this rare disease," said Chief Medical Officer Mark Sumeray in a statement.

Shares in Amryt were down 3.7% at 22.52 pence Monday.

By Hana Stewart-Smith;; @HanaSSAllNews

Copyright 2017 Alliance News Limited. All Rights Reserved.

Alliance News

Back to Alliance News

Share Price, Share Chat, Stock Market news at
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.